NDAORALTABLET
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
DIOVAN HCT (valsartan and hydrochlorothiazide) by Novartis is angiotensin 2 receptor antagonists [moa]. Approved for thiazide diuretic [epc]. First approved in 1998.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIOVAN HCT is an oral tablet combination of valsartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a thiazide diuretic) approved by the FDA in March 1998. It is indicated for the treatment of hypertension, leveraging dual mechanisms to lower blood pressure through vasodilation and sodium/fluid reduction. The product represents a standard combination therapy approach in antihypertensive management and serves as a second-line or maintenance therapy option for patients requiring multi-drug blood pressure control.
$0.0BPart D
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Thiazide Diuretic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
Started Oct 2006
601 enrolled
Hypertension
Career Relevance
Zero open positions are currently linked to DIOVAN HCT based on the data provided. Roles that may historically exist include brand managers focused on legacy product management, patient access specialists managing prior authorization and formulary navigation, and regional sales teams. Critical skills include deep knowledge of hypertension treatment algorithms, managed care contracting, and generic transition strategies, though career growth opportunities in this product area are limited given its mature, declining market position.
Worked on DIOVAN HCT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.